We were honored to feature Dr. Laurence Klotz, an acknowledged authority on active surveillance for the management of low-risk prostate cancer. Dr. Klotz is Professor in the Department of Surgery, University of Toronto Division of Urology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Dr. Klotz and panelists discussed evidence supporting value of active surveillance as a management strategy for men who are diagnosed with low- or very low-risk forms of prostate cancer. Dr. Klotz spoke particularly about factors that are key to the high-quality implementation of active surveillance, including accumulating evidence that true Gleason 6 disease is not associated with any significant risk for metastasis, importance of early identification of patients who do, in fact, have real risk for disease progression over time, are therefore not good candidates for active surveillance, and managing these patients, evolving strategies to minimize need for overly frequent (i.e., annual) biopsies, including potential role of multiparametric MRIs and new biomarkers, as also whether active surveillance is appropriate for a subset of men with Gleason 3 + 4 = 7 disease who have a very small volume Gleason pattern 4 disease.
On the panel were Mike Scott, Thomas N. Krik, Tony Crispino and Walter Green Jr.
Sorry we couldn't complete your registration. Please try again.
You must accept the Terms and conditions to register